Recombinant Anti-ERCC8 antibody [EPR9237] (ab137033)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR9237] to ERCC8
- Suitable for: IP, WB
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-ERCC8 antibody [EPR9237]
See all ERCC8 primary antibodies -
Description
Rabbit monoclonal [EPR9237] to ERCC8 -
Host species
Rabbit -
Tested applications
Suitable for: IP, WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: HAP1, HeLa, HepG2, 293T, and MOLT-4 cell lysates; IP: HeLa whole cell lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR9237 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab137033 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IP |
1/10 - 1/100.
|
|
WB |
1/1000 - 1/10000. Predicted molecular weight: 44 kDa.
|
Notes |
---|
IP
1/10 - 1/100. |
WB
1/1000 - 1/10000. Predicted molecular weight: 44 kDa. |
Target
-
Function
Substrate-recognition component of the CSA complex, a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex, involved in transcription-coupled nucleotide excision repair. The CSA complex (DCX(ERCC8) complex) promotes the ubiquitination and subsequent proteasomal degradation of ERCC6 in a UV-dependent manner; ERCC6 degradation is essential for the recovery of RNA synthesis after transcription-coupled repair. It is required for the recruitement of XAB2, HMGN1 and TCEA1/TFIIS to a transcription-coupled repair complex which removes RNA polymerase II-blocking lesions from the transcribed strand of active genes. -
Pathway
Protein modification; protein ubiquitination. -
Involvement in disease
Defects in ERCC8 are the cause of Cockayne syndrome type A (CSA) [MIM:216400]. Cockayne syndrome is a rare disorder characterized by cutaneous sensitivity to sunlight, abnormal and slow growth, cachectic dwarfism, progeroid appearance, progressive pigmentary retinopathy and sensorineural deafness. There is delayed neural development and severe progressive neurologic degeneration resulting in mental retardation. Two clinical forms are recognized: in the classical form or Cockayne syndrome type 1, the symptoms are progressive and typically become apparent within the first few years or life; the less common Cockayne syndrome type 2 is characterized by more severe symptoms that manifest prenatally. Cockayne syndrome shows some overlap with certain forms of xeroderma pigmentosum. Unlike xeroderma pigmentosum, patients with Cockayne syndrome do not manifest increased freckling and other pigmentation abnormalities in the skin and have no significant increase in skin cancer. -
Sequence similarities
Contains 5 WD repeats. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 1161 Human
- Omim: 609412 Human
- SwissProt: Q13216 Human
- Unigene: 435237 Human
-
Alternative names
- CKN1 antibody
- Cockayne syndrome type A antibody
- Cockayne syndrome WD repeat protein CSA antibody
see all
Images
-
All lanes : Anti-ERCC8 antibody [EPR9237] (ab137033) at 1/1000 dilution (Purified)
Lane 1 : MOLT-4 (Human lymphoblastic leukemia T lymphoblast) whole cell lysate
Lane 2 : 293T (Human embryonic kidney epithelial cell) whole cell lysate
Lane 3 : HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/5000 dilution
Predicted band size: 44 kDa -
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: ERCC8 knockout HAP1 cell lysate (20 µg)
Lane 3: HeLa cell lysate (20 µg)
Lane 4: Molt-4 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab137033 observed at 44 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab137033 was shown to recognize ERCC8 when ERCC8 knockout samples were used, along with additional cross-reactive bands. Wild-type and ERCC8 knockout samples were subjected to SDS-PAGE. ab137033 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/2000 respectively, and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging. -
Purified ab137033 at 1/80 dilution (2µg) immunoprecipitating ERCC8 in HeLa whole cell lysate.
Lane 1 (input): HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate 10µg
Lane 2 (+): ab137033 + HeLa whole cell lysate.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab137033 in HeLa whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/5000 dilution) was used for Western blotting.
Blocking Buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM/TBST.
Observed band size: 44 kDa
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (10)
ab137033 has been referenced in 10 publications.
- Kumar N et al. Global and transcription-coupled repair of 8-oxoG is initiated by nucleotide excision repair proteins. Nat Commun 13:974 (2022). PubMed: 35190564
- Gauhar Z et al. A Novel Missense Mutation in ERCC8 Co-Segregates with Cerebellar Ataxia in a Consanguineous Pakistani Family. Cells 11:N/A (2022). PubMed: 36231052
- Liebelt F et al. Transcription-coupled nucleotide excision repair is coordinated by ubiquitin and SUMO in response to ultraviolet irradiation. Nucleic Acids Res 48:231-248 (2020). PubMed: 31722399
- Okur MN et al. Cockayne syndrome group A and B proteins function in rRNA transcription through nucleolin regulation. Nucleic Acids Res 48:2473-2485 (2020). PubMed: 31970402
- Nakazawa Y et al. Ubiquitination of DNA Damage-Stalled RNAPII Promotes Transcription-Coupled Repair. Cell 180:1228-1244.e24 (2020). PubMed: 32142649
- Wienholz F et al. FACT subunit Spt16 controls UVSSA recruitment to lesion-stalled RNA Pol II and stimulates TC-NER. Nucleic Acids Res N/A:N/A (2019). PubMed: 30715484
- Crochemore C et al. CSB promoter downregulation via histone H3 hypoacetylation is an early determinant of replicative senescence. Nat Commun 10:5576 (2019). PubMed: 31811121
- Slyskova J et al. Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage. Nucleic Acids Res 46:9537-9549 (2018). PubMed: 30137419
- Pines A et al. TRiC controls transcription resumption after UV damage by regulating Cockayne syndrome protein A. Nat Commun 9:1040 (2018). WB . PubMed: 29531219
- Iyama T & Wilson DM Elements That Regulate the DNA Damage Response of Proteins Defective in Cockayne Syndrome. J Mol Biol 428:62-78 (2016). PubMed: 26616585